English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the zaia usage as premium feature

ZAIA

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the access of premium content as premium feature

Premium Content

Zendy Tools

Zendy Open

Correct staging is the most crucial for the treatment outcome in cancer management. Molecular imaging with 18 F-fluoroestradiol (FES) positron emission tomography-computed tomography (PET-CT) targets estrogen receptor (ER) and may have a higher incremental value in diagnosis by aiding specificity. We enrolled 12 female breast cancer patients prospectively and did 18 F-FES PET-CT and 18 F-fluorodeoxyglucose (FDG) PET-CT within 1 week interval time. Lesion detection sensitivity was compared for a total number of lesions and for nonhepatic lesions only by McNemar test. 18 F-FES PET-CT was taken as reference in case of indeterminate lesions. The incremental value reported by identifying 18 F-FES exclusive lesions and by characterization of 18 F-FDG indeterminate lesions. Spearman rank test was used to correlate ER expression and maximum standardized uptake value (SUVmax). Two ER-negative patients with no 18 F-FES uptake were excluded. Ten ER-positive patients with 154 disease lesions were finally analyzed. 18 F-FDG picked-up 142 lesions (sensitivity 92.21%), whereas 18 F-FES picked-up 116 lesions (sensitivity 75.32%) and this difference was statistically significant. For nonhepatic lesions ( n = 136) detectability, 18 F-FDG picked-up 124 (sensitivity 91.18%), whereas 18 F-FES picked-up 116 (sensitivity 85.29%) lesions and this difference was not statistically significant. Beside 12 exclusive lesions, 18 F-FES characterized 41 (27.5%) 18 F-FDG indeterminate lesions. Overall 18 F-FES impacted 20% patient management. The positive trend was also seen with 18 F-FES SUVmax with ER expression and negative with 18 F-FDG SUVmax. We conclude, 18 F-FDG has overall better sensitivity than 18 F-FES PET-CT, however for nonhepatic metastasis difference was not significant. 18 F-FES PET-CT better-characterized lesions and impacted 20% patient management. Therefore, 18 F-FES PET-CT should be used with 18 F-FDG PET-CT in strongly ER expressing patients for better specificity.

world journal of nuclear medicine

Can 18F-Fluoroestradiol positron emission tomography become a new imaging standard in the estrogen receptor-positive breast cancer patient: A prospective comparative study with 18F-Fluorodeoxyglucose positron emission tomography?